EA200900155A1 - Модуляторы фармакокинетических свойств лекарственных средств - Google Patents
Модуляторы фармакокинетических свойств лекарственных средствInfo
- Publication number
- EA200900155A1 EA200900155A1 EA200900155A EA200900155A EA200900155A1 EA 200900155 A1 EA200900155 A1 EA 200900155A1 EA 200900155 A EA200900155 A EA 200900155A EA 200900155 A EA200900155 A EA 200900155A EA 200900155 A1 EA200900155 A1 EA 200900155A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- compounds
- modulators
- medicines
- pharmacokinetic properties
- introduction
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C209/00—Preparation of compounds containing amino groups bound to a carbon skeleton
- C07C209/68—Preparation of compounds containing amino groups bound to a carbon skeleton from amines, by reactions not involving amino groups, e.g. reduction of unsaturated amines, aromatisation, or substitution of the carbon skeleton
- C07C209/78—Preparation of compounds containing amino groups bound to a carbon skeleton from amines, by reactions not involving amino groups, e.g. reduction of unsaturated amines, aromatisation, or substitution of the carbon skeleton from carbonyl compounds, e.g. from formaldehyde, and amines having amino groups bound to carbon atoms of six-membered aromatic rings, with formation of methylene-diarylamines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/005—Enzyme inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/05—Dipeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C227/00—Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C227/14—Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton from compounds containing already amino and carboxyl groups or derivatives thereof
- C07C227/16—Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton from compounds containing already amino and carboxyl groups or derivatives thereof by reactions not involving the amino or carboxyl groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C227/00—Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C227/14—Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton from compounds containing already amino and carboxyl groups or derivatives thereof
- C07C227/18—Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton from compounds containing already amino and carboxyl groups or derivatives thereof by reactions involving amino or carboxyl groups, e.g. hydrolysis of esters or amides, by formation of halides, salts or esters
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C315/00—Preparation of sulfones; Preparation of sulfoxides
- C07C315/04—Preparation of sulfones; Preparation of sulfoxides by reactions not involving the formation of sulfone or sulfoxide groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D277/24—Radicals substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D277/28—Radicals substituted by nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D277/30—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
- C07K5/06026—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
- C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
- C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
- C07K5/06052—Val-amino acid
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Virology (AREA)
- Molecular Biology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Gastroenterology & Hepatology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- AIDS & HIV (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Steroid Compounds (AREA)
- Medicinal Preparation (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Physics & Mathematics (AREA)
Abstract
Предложены соединения формулы I и их фармацевтически приемлемые соли, где значения радикалов указаны в формуле изобретения, сольват и/или сложный эфир. Предложены композиции, содержащие такие соединения, способы лечения, включающие введение таких соединений, и способы лечения, включающие введение таких соединений совместно по крайней мере с одним дополнительным терапевтическим агентом.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US81931506P | 2006-07-07 | 2006-07-07 | |
US83237106P | 2006-07-21 | 2006-07-21 | |
US90322807P | 2007-02-23 | 2007-02-23 | |
PCT/US2007/015604 WO2008010921A2 (en) | 2006-07-07 | 2007-07-06 | Modulators of pharmacokinetic properties of therapeutics |
Publications (2)
Publication Number | Publication Date |
---|---|
EA200900155A1 true EA200900155A1 (ru) | 2009-06-30 |
EA020489B1 EA020489B1 (ru) | 2014-11-28 |
Family
ID=38729072
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA200900155A EA020489B1 (ru) | 2006-07-07 | 2007-07-06 | Модуляторы фармакокинетических свойств лекарственных средств |
EA201270738A EA025845B1 (ru) | 2006-07-07 | 2007-07-06 | Модуляторы фармакокинетических свойств лекарственных средств |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA201270738A EA025845B1 (ru) | 2006-07-07 | 2007-07-06 | Модуляторы фармакокинетических свойств лекарственных средств |
Country Status (33)
Country | Link |
---|---|
US (11) | US7939553B2 (ru) |
EP (4) | EP2487165B1 (ru) |
JP (2) | JP4881433B2 (ru) |
KR (3) | KR101636221B1 (ru) |
CN (2) | CN103275033B (ru) |
AP (1) | AP2985A (ru) |
AR (1) | AR061838A1 (ru) |
AU (1) | AU2007275860C1 (ru) |
BR (1) | BRPI0714055B8 (ru) |
CA (1) | CA2653374A1 (ru) |
CY (2) | CY1116688T1 (ru) |
DK (1) | DK2049506T5 (ru) |
EA (2) | EA020489B1 (ru) |
ES (3) | ES2611308T3 (ru) |
FR (1) | FR15C0078I2 (ru) |
HK (2) | HK1232217A1 (ru) |
HR (2) | HRP20090077B1 (ru) |
HU (1) | HUE025565T4 (ru) |
IL (2) | IL195488A (ru) |
LT (1) | LTC2049506I2 (ru) |
LU (1) | LU92864I2 (ru) |
ME (1) | ME02258B (ru) |
MX (1) | MX2009000234A (ru) |
NL (1) | NL300780I1 (ru) |
NO (4) | NO343776B1 (ru) |
NZ (1) | NZ573060A (ru) |
PL (1) | PL2049506T3 (ru) |
PT (2) | PT2049506E (ru) |
RS (1) | RS54237B9 (ru) |
SG (1) | SG183007A1 (ru) |
SI (1) | SI2049506T1 (ru) |
TW (2) | TWI411613B (ru) |
WO (1) | WO2008010921A2 (ru) |
Families Citing this family (72)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7786153B2 (en) | 2005-03-02 | 2010-08-31 | Abbott Laboratories Inc. | Compounds that are useful for improving pharmacokinetics |
CN103275033B (zh) | 2006-07-07 | 2015-04-29 | 吉里德科学公司 | 治疗剂的药代动力学特性调节剂 |
EP2465855A1 (en) * | 2006-08-31 | 2012-06-20 | Abbott Laboratories | Cytochrome P450 oxidase inhibitors and uses thereof |
AU2013204817B2 (en) * | 2007-02-23 | 2015-05-07 | Gilead Sciences, Inc. | Modulators of pharmacokinetic properties of therapeutics |
AU2015204378B2 (en) * | 2007-02-23 | 2017-03-09 | Gilead Sciences, Inc. | Modulators of pharmacokinetic properties of therapeutics |
PL2487163T3 (pl) | 2007-02-23 | 2017-04-28 | Gilead Sciences, Inc. | Modulatory farmakokinetycznych właściwości środków terapeutycznych |
US9891239B2 (en) * | 2007-02-23 | 2018-02-13 | Gilead Sciences, Inc. | Modulators of pharmacokinetic properties of therapeutics |
US7964580B2 (en) | 2007-03-30 | 2011-06-21 | Pharmasset, Inc. | Nucleoside phosphoramidate prodrugs |
SG182229A1 (en) * | 2007-06-29 | 2012-07-30 | Gilead Sciences Inc | Therapeutic compositions and the use thereof |
US20090093482A1 (en) * | 2007-06-29 | 2009-04-09 | Gilead Sciences, Inc. | Therapeutic compositions and methods |
CN101796040A (zh) * | 2007-07-06 | 2010-08-04 | 吉里德科学公司 | 治疗剂的药代动力学特性调节剂 |
JP2011503231A (ja) * | 2007-11-20 | 2011-01-27 | コンサート ファーマシューティカルズ インコーポレイテッド | Hcv感染処置のためのペプチド |
AU2008346823B2 (en) * | 2008-01-04 | 2015-03-12 | Gilead Sciences, Inc. | Inhibitors of cytochrome P450 |
WO2009094190A2 (en) | 2008-01-25 | 2009-07-30 | Chimerix, Inc. | Methods of treating viral infections |
US10039718B2 (en) | 2008-05-02 | 2018-08-07 | Gilead Sciences, Inc. | Use of solid carrier particles to improve the processability of a pharmaceutical agent |
AR074897A1 (es) | 2008-12-23 | 2011-02-23 | Pharmasset Inc | Fosforamidatos de nucleosidos |
SG172361A1 (en) | 2008-12-23 | 2011-07-28 | Pharmasset Inc | Nucleoside analogs |
AU2009329872B2 (en) | 2008-12-23 | 2016-07-07 | Gilead Pharmasset Llc | Synthesis of purine nucleosides |
SG173544A1 (en) * | 2009-02-06 | 2011-09-29 | Gilead Sciences Inc | Tablets for combination therapy |
UA108738C2 (uk) | 2009-04-03 | 2015-06-10 | Спосіб одержання інгібітора цитохром р450 монооксигенази та залучені проміжні сполуки | |
US8618076B2 (en) | 2009-05-20 | 2013-12-31 | Gilead Pharmasset Llc | Nucleoside phosphoramidates |
TWI583692B (zh) | 2009-05-20 | 2017-05-21 | 基利法瑪席特有限責任公司 | 核苷磷醯胺 |
WO2011123672A1 (en) | 2010-03-31 | 2011-10-06 | Pharmasset, Inc. | Purine nucleoside phosphoramidate |
EP2752422B1 (en) | 2010-03-31 | 2017-08-16 | Gilead Pharmasset LLC | Stereoselective synthesis of phosphorus containing actives |
EP2418196A1 (en) * | 2010-07-29 | 2012-02-15 | IMTM GmbH | Dual alanyl-aminopeptidase and dipeptidyl-peptidase IV inhibitors |
MY158809A (en) * | 2010-09-22 | 2016-11-15 | Craun Res Sdn Bhd | Pharmaceutical compositions for calanolides, their derivatives and analogues, and process for producing the same |
WO2012045007A1 (en) | 2010-10-01 | 2012-04-05 | Gilead Sciences, Inc. | Method of preparation of (4 - {4 -acetylamino- 2 - [3- ( 2 - isopropyl - thiazol - 4 - ylmethyl) - 3 -methyl - ureido] - butyryl amino} -1 -benzyl- 5 -phenyl- pentyl) -carbamic acid thiazol - 5 - ylmethyl ester |
ES2716158T3 (es) | 2010-11-30 | 2019-06-10 | Gilead Pharmasset Llc | 2'-spiro-nucleótidos para el tratamiento de hepatitis C |
WO2012088153A1 (en) * | 2010-12-21 | 2012-06-28 | Gilead Sciences, Inc. | Inhibitors of cytochrome p450 |
US20140187771A1 (en) * | 2011-05-02 | 2014-07-03 | Gilead Sciences, Inc. | Amorphous solid salts |
CN103826616B (zh) | 2011-07-07 | 2016-08-10 | 爱尔兰詹森科学公司 | 地瑞纳韦组合配制品 |
CA2845553C (en) | 2011-08-16 | 2019-05-28 | Gilead Sciences, Inc. | Tenofovir alafenamide hemifumarate |
MD4589C1 (ru) | 2011-09-16 | 2019-03-31 | Gilead Pharmasset Llc | Фармацевтическая композиция с содержанием софосбувира и ее использование при лечении вирусного гепатита С |
US8889159B2 (en) | 2011-11-29 | 2014-11-18 | Gilead Pharmasset Llc | Compositions and methods for treating hepatitis C virus |
US9089574B2 (en) | 2011-11-30 | 2015-07-28 | Emory University | Antiviral JAK inhibitors useful in treating or preventing retroviral and other viral infections |
US20150004239A1 (en) | 2012-01-12 | 2015-01-01 | Gilead Sciences, Inc. | Pharmaceutical compositions and methods for their preparation |
SG11201404527QA (en) | 2012-02-03 | 2014-08-28 | Gilead Sciences Inc | Methods and intermediates for preparing pharmaceutical agents |
JP2015508822A (ja) | 2012-03-01 | 2015-03-23 | ギリアード サイエンシーズ, インコーポレイテッド | 噴霧乾燥製剤 |
CN104540813A (zh) * | 2012-06-27 | 2015-04-22 | 默沙东公司 | 磺酰胺衍生物以及使用它们用于改善药物的药物动力学的方法 |
WO2014000178A1 (en) * | 2012-06-27 | 2014-01-03 | Merck Sharp & Dohme Corp. | Sulfonamide derivatives and methods of use thereof for improving the pharmacokinetics of a drug |
CN103694196A (zh) * | 2012-09-27 | 2014-04-02 | 上海迪赛诺化学制药有限公司 | 细胞色素p450单加氧酶抑制剂中间体及其制法和用途 |
US20160200716A1 (en) * | 2012-12-26 | 2016-07-14 | Assia Chemical Industries Ltd. | Cobicistat dichlohydrate salt |
NZ625087A (en) | 2013-01-31 | 2017-05-26 | Gilead Pharmasset Llc | Combination formulation of two antiviral compounds |
WO2014194519A1 (en) | 2013-06-07 | 2014-12-11 | Merck Sharp & Dohme Corp. | Imidazole derivatives and methods of use thereof for improving pharmacokinetics of drug |
CN104370777A (zh) * | 2013-08-13 | 2015-02-25 | 上海迪赛诺化学制药有限公司 | 合成(2r,5r)-1,6-二苯基己烷-2,5-二胺及其盐的中间体及所述中间体的制备方法和应用 |
ES2900570T3 (es) | 2013-08-27 | 2022-03-17 | Gilead Pharmasset Llc | Formulación de combinación de dos compuestos antivirales |
WO2015070366A1 (en) | 2013-11-12 | 2015-05-21 | Merck Sharp & Dohme Corp. | Aryl linked imidazole and triazole derivatives and methods of use thereof for improving the pharmacokinetics of a drug |
WO2015070367A1 (en) | 2013-11-12 | 2015-05-21 | Merck Sharp & Dohme Corp. | Piperidine or piperazine linked imidazole and triazole derivatives and methods of use thereof for improving the pharmacokinetics of a drug |
WO2015079415A1 (en) | 2013-11-29 | 2015-06-04 | Mylan Laboratories Ltd. | Amorphous cobicistat solid dispersion |
DK3236972T3 (en) | 2014-12-26 | 2021-10-04 | Univ Emory | Antivirale N4-hydroxycytidin-derivativer |
CN105198829B (zh) * | 2015-08-15 | 2017-10-31 | 浙江永宁药业股份有限公司 | 一种可比司他中间体的制备方法及其中间体和用途 |
TW201728582A (zh) | 2016-01-28 | 2017-08-16 | 基利科學股份有限公司 | 結晶型 |
US10653681B2 (en) | 2016-03-16 | 2020-05-19 | Recurium Ip Holdings, Llc | Analgesic compounds |
CN105884760B (zh) * | 2016-06-13 | 2019-01-04 | 厦门市蔚嘉化学科技有限公司 | 一种可比司他中间体的制备方法 |
CN107674039A (zh) * | 2016-08-01 | 2018-02-09 | 上海朴颐化学科技有限公司 | 一种可比西他中间体的制备方法 |
JP6764017B2 (ja) * | 2016-08-04 | 2020-09-30 | ギリアード サイエンシーズ, インコーポレイテッド | がんの処置での使用のためのコビシスタット |
EP3518935A1 (en) | 2016-09-27 | 2019-08-07 | Gilead Sciences, Inc. | Therapeutic compositions for treatment of human immunodeficiency virus |
US11185548B2 (en) | 2016-12-23 | 2021-11-30 | Helmholtz Zentrum Munchen—Deutsches Forschungszentrum Für Gesundheit Und Umwelt (Gmbh) | Inhibitors of cytochrome P450 family 7 subfamily B member 1 (CYP7B1) for use in treating diseases |
SI3661937T1 (sl) | 2017-08-01 | 2021-11-30 | Gilead Sciences, Inc. | Kristalinične oblike etil((S)-((((2R,5R)-5-(6-amino-9H-purin-9-IL)-4- fluoro-2,5-dihidrofuran-2-IL)oksi)metil)(fenoksi)fosforil)-L-alaninata (GS-9131) za zdravljenje virusnih okužb |
SG11202004403QA (en) | 2017-12-07 | 2020-06-29 | Univ Emory | N4-hydroxycytidine and derivatives and anti-viral uses related thereto |
US20220010054A1 (en) * | 2018-11-26 | 2022-01-13 | Mitsubishi Gas Chemical Company, Inc. | Aqueous epoxy resin composition and cured product of same |
CN111329858B (zh) * | 2018-12-18 | 2022-09-20 | 深圳先进技术研究院 | 一种小分子抑制剂在抑制病毒沉默抑制蛋白中的应用 |
EP4121437A1 (en) | 2020-03-20 | 2023-01-25 | Gilead Sciences, Inc. | Prodrugs of 4'-c-substituted-2-halo-2'-deoxyadenosine nucleosides and methods of making and using the same |
TWI815194B (zh) | 2020-10-22 | 2023-09-11 | 美商基利科學股份有限公司 | 介白素2-Fc融合蛋白及使用方法 |
WO2022103758A1 (en) | 2020-11-11 | 2022-05-19 | Gilead Sciences, Inc. | METHODS OF IDENTIFYING HIV PATIENTS SENSITIVE TO THERAPY WITH gp120 CD4 BINDING SITE-DIRECTED ANTIBODIES |
WO2023102523A1 (en) | 2021-12-03 | 2023-06-08 | Gilead Sciences, Inc. | Therapeutic compounds for hiv virus infection |
TW202337439A (zh) | 2021-12-03 | 2023-10-01 | 美商基利科學股份有限公司 | 用於hiv病毒感染之治療性化合物 |
US20230203071A1 (en) | 2021-12-03 | 2023-06-29 | Zhimin Du | Therapeutic compounds for hiv virus infection |
TW202400165A (zh) | 2022-04-06 | 2024-01-01 | 美商基利科學股份有限公司 | 橋聯三環胺甲醯基吡啶酮化合物及其用途 |
WO2024006982A1 (en) | 2022-07-01 | 2024-01-04 | Gilead Sciences, Inc. | Therapeutic compounds useful for the prophylactic or therapeutic treatment of an hiv virus infection |
US20240083984A1 (en) | 2022-08-26 | 2024-03-14 | Gilead Sciences, Inc. | Dosing and scheduling regimen for broadly neutralizing antibodies |
WO2024076915A1 (en) | 2022-10-04 | 2024-04-11 | Gilead Sciences, Inc. | 4'-thionucleoside analogues and their pharmaceutical use |
Family Cites Families (61)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3354866A (en) * | 1966-04-25 | 1967-11-28 | Frank D Karkoska | Coating apparatus including means to rotate and translate a rod-substrate |
US3882114A (en) * | 1967-10-26 | 1975-05-06 | Oreal | N-(morpholinomethyl carbamyl) cysteamine and glycine |
GB1339764A (en) * | 1971-03-29 | 1973-12-05 | Ici Ltd | Pyridine derivatives |
US3957774A (en) * | 1972-04-17 | 1976-05-18 | L'oreal | N-morpholinomethyl-n-'-substituted ethyl and propylureas |
US5142056A (en) * | 1989-05-23 | 1992-08-25 | Abbott Laboratories | Retroviral protease inhibiting compounds |
HU186777B (en) | 1981-07-09 | 1985-09-30 | Magyar Tudomanyos Akademia | Process for producing complex-forming agents of crown-ether base and ionoselective membranelektrodes containing them |
DE3478684D1 (en) * | 1983-11-02 | 1989-07-20 | Magyar Tudomanyos Akademia | Crown ether derivatives |
US5362912A (en) * | 1989-05-23 | 1994-11-08 | Abbott Laboratories | Process for the preparation of a substituted diaminodiol |
US5539122A (en) * | 1989-05-23 | 1996-07-23 | Abbott Laboratories | Retroviral protease inhibiting compounds |
US5354866A (en) * | 1989-05-23 | 1994-10-11 | Abbott Laboratories | Retroviral protease inhibiting compounds |
EP0428849A3 (en) | 1989-09-28 | 1991-07-31 | Hoechst Aktiengesellschaft | Retroviral protease inhibitors |
US5204466A (en) | 1990-02-01 | 1993-04-20 | Emory University | Method and compositions for the synthesis of bch-189 and related compounds |
US6703396B1 (en) | 1990-02-01 | 2004-03-09 | Emory University | Method of resolution and antiviral activity of 1,3-oxathiolane nuclesoside enantiomers |
US5914331A (en) | 1990-02-01 | 1999-06-22 | Emory University | Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane |
IE20010533A1 (en) * | 1990-11-20 | 2003-03-05 | Abbott Lab | Intermediates for preparing retroviral protease inhibiting compounds |
JPH06127981A (ja) | 1992-03-03 | 1994-05-10 | Fuainiteii Kk | 複合複層ガラス及びそれを使用した窓 |
US5556418A (en) * | 1993-07-06 | 1996-09-17 | Pappas; Panagiotis T. | Method and apparatus for pulsed magnetic induction |
US5968942A (en) * | 1992-08-25 | 1999-10-19 | G. D. Searle & Co. | α- and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors |
KR100360964B1 (ko) * | 1992-12-29 | 2002-11-22 | 아보트 러보러터리즈 | 레트로바이러스성 프로테아제 억제 화합물의 중간체의제조방법 |
US5567592A (en) * | 1994-02-02 | 1996-10-22 | Regents Of The University Of California | Screening method for the identification of bioenhancers through the inhibition of P-glycoprotein transport in the gut of a mammal |
UA49803C2 (ru) * | 1994-06-03 | 2002-10-15 | Дж.Д. Сьорль Енд Ко | Способ лечения ретровирусных инфекций |
US5567823A (en) * | 1995-06-06 | 1996-10-22 | Abbott Laboratories | Process for the preparation of an HIV protease inhibiting compound |
US6037157A (en) * | 1995-06-29 | 2000-03-14 | Abbott Laboratories | Method for improving pharmacokinetics |
US5763464A (en) * | 1995-11-22 | 1998-06-09 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Retroviral agents containing anthranilamide, substituted benzamide and other subunits, and methods of using same |
US5922695A (en) | 1996-07-26 | 1999-07-13 | Gilead Sciences, Inc. | Antiviral phosphonomethyoxy nucleotide analogs having increased oral bioavarilability |
US5935946A (en) | 1997-07-25 | 1999-08-10 | Gilead Sciences, Inc. | Nucleotide analog composition and synthesis method |
WO1999033792A2 (en) * | 1997-12-24 | 1999-07-08 | Vertex Pharmaceuticals Incorporated | Prodrugs os aspartyl protease inhibitors |
FR2773994B1 (fr) | 1998-01-23 | 2002-10-11 | Univ Nice Sophia Antipolis | Prodrogues issues d'anti-proteases inhibitrices du virus de l'immunodeficience humaine (vih) pour l'amelioration de leur biodisponibilite, de leur tropisme vers et/ou de leur delivrance dans le systeme nerveux central |
FR2779653B1 (fr) * | 1998-06-11 | 2002-12-20 | Inst Nat Sante Rech Med | Utilisation de composes modulateurs du proteasome en therapie |
SI1183026T1 (sl) * | 1999-06-04 | 2006-10-31 | Abbott Lab | Izboljsane farmacevtske spojine, vsebujoce ritonavir |
NZ518580A (en) | 1999-10-06 | 2004-01-30 | Us Gov Health & Human Serv | Hexahydrofuro[2,3-B]furan-3-YL-N- {3-[1,3-benzodioxol-5-ylsulfonyl) (isobutyl) amino]-1-benzyl-2-hydroxypropyl} carbamate as retroviral protease inhibitor |
US6252336B1 (en) | 1999-11-08 | 2001-06-26 | Cts Corporation | Combined piezoelectric silent alarm/battery charger |
AU2001259817A1 (en) * | 2000-05-04 | 2001-11-12 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services, The National Institutes Of Health | Methods of and compounds for inhibiting calpains |
US7193065B2 (en) * | 2001-07-13 | 2007-03-20 | Roche Diagnostics Operations, Inc. | Protease inhibitor conjugates and antibodies useful in immunoassay |
US6946449B2 (en) * | 2001-07-13 | 2005-09-20 | Cv Therapeutics, Inc. | Partial and full agonists of A1 adenosine receptors |
US7285566B2 (en) | 2002-01-07 | 2007-10-23 | Erickson John W | Resistance-repellent retroviral protease inhibitors |
ES2291642T3 (es) | 2002-01-17 | 2008-03-01 | MERCK & CO., INC. | Hidroxinaftiridinoncarboxamidas utiles como inhibidores de la integrasa de vih. |
US7205413B2 (en) * | 2002-05-03 | 2007-04-17 | Transform Pharmaceuticals, Inc. | Solvates and polymorphs of ritonavir and methods of making and using the same |
DK1564210T5 (da) | 2002-11-20 | 2010-05-03 | Japan Tobacco Inc | 4-Oxoquinolinforbindelser og anvendelse deraf som HIV-integraseinhibitorer |
JP2004184681A (ja) * | 2002-12-03 | 2004-07-02 | Konica Minolta Holdings Inc | 熱現像感光材料 |
EP1923063A3 (en) | 2003-01-14 | 2009-04-08 | Gilead Sciences, Inc. | Compositions and methods for combination antiviral therapy |
TW200505441A (en) | 2003-03-24 | 2005-02-16 | Hoffmann La Roche | Non-nucleoside reverse transcriptase inhibitorsⅠ |
US7737608B2 (en) | 2003-07-30 | 2010-06-15 | The Boeing Company | Enhanced amplitude piezoelectric motor apparatus and method |
JP2005091988A (ja) * | 2003-09-19 | 2005-04-07 | Konica Minolta Medical & Graphic Inc | 熱現像感光材料及び画像形成方法 |
MXPA06004723A (es) * | 2003-10-27 | 2006-07-05 | Vertex Pharma | Combinacion para el tratamiento del hcv. |
BRPI0401742B8 (pt) | 2004-05-13 | 2021-05-25 | Cristalia Produtos Quim Farmaceuticos Ltda | composto análogo do ritonavir útil como inibidor de protease retroviral, preparação do composto análogo do ritonavir e composição farmacêutica do composto análogo do ritonavir |
MY134672A (en) | 2004-05-20 | 2007-12-31 | Japan Tobacco Inc | Stable crystal of 4-oxoquinoline compound |
JP2006003701A (ja) * | 2004-06-18 | 2006-01-05 | Konica Minolta Medical & Graphic Inc | 熱現像感光材料および画像形成方法 |
EP2336138A3 (en) * | 2004-07-06 | 2011-11-16 | Abbott Laboratories | Prodrugs of HIV protease inhibitors |
US7786153B2 (en) * | 2005-03-02 | 2010-08-31 | Abbott Laboratories Inc. | Compounds that are useful for improving pharmacokinetics |
TWI471145B (zh) | 2005-06-13 | 2015-02-01 | Bristol Myers Squibb & Gilead Sciences Llc | 單一式藥學劑量型 |
TWI375560B (en) | 2005-06-13 | 2012-11-01 | Gilead Sciences Inc | Composition comprising dry granulated emtricitabine and tenofovir df and method for making the same |
CN103275033B (zh) | 2006-07-07 | 2015-04-29 | 吉里德科学公司 | 治疗剂的药代动力学特性调节剂 |
EP2465855A1 (en) | 2006-08-31 | 2012-06-20 | Abbott Laboratories | Cytochrome P450 oxidase inhibitors and uses thereof |
US9891239B2 (en) * | 2007-02-23 | 2018-02-13 | Gilead Sciences, Inc. | Modulators of pharmacokinetic properties of therapeutics |
SG182229A1 (en) | 2007-06-29 | 2012-07-30 | Gilead Sciences Inc | Therapeutic compositions and the use thereof |
US20090093482A1 (en) | 2007-06-29 | 2009-04-09 | Gilead Sciences, Inc. | Therapeutic compositions and methods |
CN101796040A (zh) * | 2007-07-06 | 2010-08-04 | 吉里德科学公司 | 治疗剂的药代动力学特性调节剂 |
EP2245456B1 (en) | 2007-12-27 | 2013-02-13 | Baxter International Inc. | Method and compositions for specifically detecting physiologically acceptable polymer molecules |
US10039718B2 (en) | 2008-05-02 | 2018-08-07 | Gilead Sciences, Inc. | Use of solid carrier particles to improve the processability of a pharmaceutical agent |
SG173544A1 (en) | 2009-02-06 | 2011-09-29 | Gilead Sciences Inc | Tablets for combination therapy |
-
2007
- 2007-07-06 CN CN201310141408.6A patent/CN103275033B/zh active Active
- 2007-07-06 PT PT78360070T patent/PT2049506E/pt unknown
- 2007-07-06 HU HUE07836007A patent/HUE025565T4/en unknown
- 2007-07-06 CN CN2007800256073A patent/CN101490023B/zh active Active
- 2007-07-06 BR BRPI0714055A patent/BRPI0714055B8/pt active IP Right Grant
- 2007-07-06 ES ES12167594.6T patent/ES2611308T3/es active Active
- 2007-07-06 AR ARP070103029A patent/AR061838A1/es active IP Right Grant
- 2007-07-06 PL PL07836007T patent/PL2049506T3/pl unknown
- 2007-07-06 EP EP12167594.6A patent/EP2487165B1/en active Active
- 2007-07-06 JP JP2009518393A patent/JP4881433B2/ja active Active
- 2007-07-06 ES ES07836007.0T patent/ES2546378T3/es active Active
- 2007-07-06 EA EA200900155A patent/EA020489B1/ru active Protection Beyond IP Right Term
- 2007-07-06 KR KR1020157008020A patent/KR101636221B1/ko active IP Right Grant
- 2007-07-06 EA EA201270738A patent/EA025845B1/ru active Protection Beyond IP Right Term
- 2007-07-06 EP EP07836007.0A patent/EP2049506B9/en active Active
- 2007-07-06 ES ES16180602T patent/ES2796275T3/es active Active
- 2007-07-06 CA CA002653374A patent/CA2653374A1/en not_active Abandoned
- 2007-07-06 NZ NZ573060A patent/NZ573060A/en unknown
- 2007-07-06 EP EP20167933.9A patent/EP3696171A1/en active Pending
- 2007-07-06 EP EP16180602.1A patent/EP3112355B1/en active Active
- 2007-07-06 MX MX2009000234A patent/MX2009000234A/es active IP Right Grant
- 2007-07-06 WO PCT/US2007/015604 patent/WO2008010921A2/en active Application Filing
- 2007-07-06 RS RS20150590A patent/RS54237B9/sr unknown
- 2007-07-06 DK DK07836007.0T patent/DK2049506T5/en active
- 2007-07-06 AP AP2008004720A patent/AP2985A/xx active
- 2007-07-06 KR KR1020137033735A patent/KR20140004808A/ko not_active Application Discontinuation
- 2007-07-06 ME MEP-2015-590A patent/ME02258B/me unknown
- 2007-07-06 PT PT121675946T patent/PT2487165T/pt unknown
- 2007-07-06 AU AU2007275860A patent/AU2007275860C1/en active Active
- 2007-07-06 US US11/825,605 patent/US7939553B2/en active Active
- 2007-07-06 KR KR1020097002544A patent/KR101477822B1/ko active IP Right Grant
- 2007-07-06 TW TW096124727A patent/TWI411613B/zh active
- 2007-07-06 TW TW102126891A patent/TWI496778B/zh active
- 2007-07-06 SG SG2012050464A patent/SG183007A1/en unknown
- 2007-07-06 SI SI200731667T patent/SI2049506T1/sl unknown
- 2007-07-06 US US12/306,198 patent/US8067449B2/en active Active
-
2008
- 2008-11-25 IL IL195488A patent/IL195488A/en active IP Right Grant
-
2009
- 2009-02-06 NO NO20090593A patent/NO343776B1/no active Protection Beyond IP Right Term
- 2009-02-06 HR HRP20090077AA patent/HRP20090077B1/hr not_active IP Right Cessation
- 2009-06-08 HK HK17105753.7A patent/HK1232217A1/zh unknown
- 2009-06-08 HK HK09105118.7A patent/HK1126485A1/xx unknown
-
2011
- 2011-05-09 US US13/103,970 patent/US8383655B2/en active Active
- 2011-10-31 JP JP2011239688A patent/JP2012051933A/ja not_active Withdrawn
-
2013
- 2013-01-10 US US13/738,764 patent/US20130123311A1/en not_active Abandoned
- 2013-12-20 US US14/137,555 patent/US20140105859A1/en not_active Abandoned
-
2014
- 2014-04-29 IL IL232320A patent/IL232320A0/en unknown
- 2014-05-02 US US14/268,891 patent/US20150011775A1/en not_active Abandoned
-
2015
- 2015-01-20 US US14/601,132 patent/US9139541B2/en active Active
- 2015-07-08 HR HRP20150744TT patent/HRP20150744T2/hr unknown
- 2015-08-17 US US14/828,406 patent/US20160067360A1/en not_active Abandoned
- 2015-09-14 CY CY20151100800T patent/CY1116688T1/el unknown
- 2015-11-06 LU LU92864C patent/LU92864I2/xx unknown
- 2015-11-11 LT LTPA2015040C patent/LTC2049506I2/lt unknown
- 2015-11-26 CY CY2015046C patent/CY2015046I1/el unknown
- 2015-12-02 FR FR15C0078C patent/FR15C0078I2/fr active Active
- 2015-12-08 NL NL300780C patent/NL300780I1/nl unknown
-
2016
- 2016-03-17 US US15/073,367 patent/US20160303088A1/en not_active Abandoned
- 2016-11-01 US US15/340,466 patent/US20170143680A1/en not_active Abandoned
-
2017
- 2017-12-05 US US15/831,703 patent/US20180221348A1/en not_active Abandoned
-
2019
- 2019-04-23 NO NO20190528A patent/NO345343B1/no unknown
- 2019-07-04 NO NO2019027C patent/NO2019027I1/no unknown
- 2019-07-19 NO NO2019031C patent/NO2019031I1/no unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA200900155A1 (ru) | Модуляторы фармакокинетических свойств лекарственных средств | |
EA200971081A1 (ru) | Пуриновые производные и их применение в качестве модуляторов толл-подобного рецептора 7 | |
CY1122761T1 (el) | Διαμορφωτες φαρμακοκινητικων ιδιοτητων θεραπευτικων παραγοντων | |
NO2020031I1 (no) | kobimetinib, inklusive farmasøytisk akseptable salter og solvater, særlig kobimetinib hemifumarat | |
MY149957A (en) | Heterocyclic inhibitors of mek and methods of use thereof | |
MX361467B (es) | Compuestos de isoindolina para uso en el tratamiento de cancer. | |
CY1112921T1 (el) | Ενεργοποιητες γλυκοκινασης πυρρολιδινονης | |
MX2009011997A (es) | Derivados de pirrolopirimidin-7-ona y su uso como farmaceuticos. | |
MX2009014235A (es) | 4-bencilaminoquinolonas, composiciones farmaceuticas que las contiene y su uso. | |
MX2009003157A (es) | Pirazoliltienopiridinas terapeuticas. | |
EA201001196A1 (ru) | Соединения 4-пиридинона и их применение для лечения рака | |
BRPI0518993A2 (pt) | composto ou um sal, solvato ou Éster farmaceuticamente aceitÁvel do mesmo, composiÇço farmacÊutica, e, uso de um composto | |
SE0401342D0 (sv) | Therapeutic compounds | |
CY1115725T1 (el) | Ενωσεις, συνθεσεις και μεθοδοι για την θεραπευτικη αγωγη των βητα-αμυλοειδικων ασθενειων και συνουκλεϊνοπαθειων | |
CY1111442T1 (el) | Ενωσεις πιπεριδινης και χρησεις αυτων | |
MXPA05012894A (es) | Benzofuranos 3-sustituidos como agentes terapeuticos. | |
DE602005010744D1 (de) | Piperazinylpyridinderivate als mittel gegen adipositas | |
SE0402925D0 (sv) | Novel Compounds | |
ATE531703T1 (de) | Benzochromenderivate | |
TW200716653A (en) | Azolopyridin-2-one derivatives as inhibitors of lipases and phospholipases | |
EA200870223A1 (ru) | Производные бензоизоиндола для лечения боли | |
TW200800993A (en) | Organic compounds | |
NO20082848L (no) | Farmasoytisk formulering for behandling av osteoartritt inneholdende klodronsyre og hyaluronsyre | |
SE0402763D0 (sv) | Nitro indazole derivatives | |
UA101312C2 (ru) | Модуляторы фармакокинетических свойств терапевтических препаратов |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
ND4A | Extension of term of a eurasian patent | ||
ND4A | Extension of term of a eurasian patent |